To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for treating extensive stage small-cell lung cancer
NICE is unable to make a recommendation on durvalumab in combination for treating untreated extensive stage small-cell lung cancer because AstraZeneca withdrew its evidence submission. We will review this decision if the company decides to make a submission in the future.
 
Status Suspended
Process STA 2018
ID number 1618

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Consultees

Companies sponsors AstraZeneca (durvalumab)
Others Department of Health and Social care
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (cisplatin, carboplatin, etoposide, gemcitabine) (CAU form not submitted, not participating)
  Cheplapharm Arzneimittel (etoposide) (CAU form not submitted, not participating)
  Consilient Health (carboplatin) (CAU form not submitted, not participating)
  Hospira UK (cisplatin, carboplatin, gemcitabine) (CAU form not submitted, not participating)
  Medac GmbH (etoposide) (CAU form not submitted, not participating)
  Sandoz (cisplatin) (CAU form not submitted, not participating)
  Ranbaxy UK (gemcitabine) (CAU form not submitted, not participating)
  Roche Products (atezolizumab) (CAU form not submitted, not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
26 October 2020 Suspended. NICE is unable to make a recommendation on durvalumab in combination for treating untreated extensive stage small-cell lung cancer because AstraZeneca withdrew its evidence submission. We will review this decision if the company decides to make a submission in the future.
11 September 2020 The Committee meeting for this appraisal which was scheduled for Wednesday 7 October 2020 has been cancelled. As a result, the expected publication date is to be confirmed. We will provide more information about this appraisal when available.
06 February 2020 Invitation to participate
19 December 2019 Following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early February 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
16 August 2019 - 16 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 May 2019 In progress. Referred 29 April 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance